REFERENCES
- Full Prescribing Information for HysinglaTM ER (hydrocodone bitartrate) Extended-Release Tablets CII.
- Larson et al. Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364–1372.
- Michna E, Duh MS, Korves C, Dahl JL. Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications. Pain Med. 2010;11:369–378.
- IMS Health NPA, based on TRx, August 2014. Accessed Oct. 20, 2014.
- 2013 National Survey on Drug Use and Health, Table 1.89A. Substance Abuse and Mental Health Services Administration. Accessed Oct. 20 2014.
- Guidance for Industry: Abuse-Deterrent Opioids- Evaluation and Labeling: Draft Guidance. US Food & Drug Administration. Accessed Oct. 20, 2014.
- Data on File, Purdue Pharma L.P.
- Acetaminophen Prescription Combination Drug Products with more than 325 mg: FDA Statement - Recommendation to Discontinue Prescribing and Dispensing. U.S. Food & Drug Administration. Accessed Oct. 20, 2014
REFERENCES
- Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press, 2011.
- National Institutes of Health. Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain. Draft Executive Summary. September 29-30, 2014.